38 trial deaths in India in 2 years but SAE reporting overkill skewing data
This article was originally published in Scrip
India has reported 38 deaths due to clinical trials in 2010 and 2011, less than 5% of the overall deaths in the country during such studies, with compensation having been paid in all but one case each year. The data are significant since they lend some credence to industry's claims that India's excessive reporting requirements for serious adverse events may be skewing clinical trial data in the country.
You may also be interested in...
Abbott is developing an extended release version of vildagliptin in India, adding a new dimension to the market dynamics for the DPP-4 inhibitor, which has seen a key patent expire. Sustained release vildagliptin products from Wockhardt and Synokem also appear to be in the works.
Years after a scathing Indian parliamentary report flagged concerns around regulatory lapses for drug approvals, an expert panel has endorsed the continued marketing of ambrisentan and everolimus in the country. But dronedarone, also featured in the report, is no longer sold by Sanofi in India.
Tecentriq cleared for extensive-stage small cell lung cancer in India but pricing remains a key constraining factor. Patient assistance schemes help but such novel therapies still unaffordable to a vast majority.